Holen Sie sich die Stockscreener-App
8.655
3.46%
-0.305
Schlusskurs vom Vortag:
$8.96
Offen:
$8.905
24-Stunden-Volumen:
408.84K
Relative Volume:
0.06
Marktkapitalisierung:
$715.90M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-314.85M
KGV:
-2.4159
EPS:
-3.5825
Netto-Cashflow:
$-283.27M
1W Leistung:
-6.38%
1M Leistung:
+65.71%
6M Leistung:
-9.99%
1J Leistung:
-12.00%
1-Tages-Spanne:
$8.625
$8.96
1-Wochen-Bereich:
$8.25
$9.27
52-Wochen-Spanne:
$1.50
$13.24
Replimune Group Inc Stock (REPL) Company Profile
Firmenname
Replimune Group Inc
Sektor
Branche
Telefon
(781) 222-9600
Adresse
500 UNICORN PARK, WOBURN, MA
Compare REPL vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
8.67 | 739.85M | 0 | -314.85M | -283.27M | -3.5825 |
VRTX
Vertex Pharmaceuticals Inc
|
449.10 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
610.65 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.98 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
279.26 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
155.44 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-13 | Herabstufung | BMO Capital Markets | Market Perform → Underperform |
| 2026-04-13 | Herabstufung | H.C. Wainwright | Buy → Sell |
| 2026-04-13 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2026-04-13 | Herabstufung | Jefferies | Buy → Hold |
| 2026-04-13 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2026-04-13 | Herabstufung | Wedbush | Outperform → Neutral |
| 2026-04-10 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-11-03 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
| 2025-10-27 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-10-20 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2025-10-20 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-10-20 | Hochstufung | Wedbush | Neutral → Outperform |
| 2025-09-19 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-07-30 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-07-23 | Herabstufung | BMO Capital Markets | Outperform → Underperform |
| 2025-07-23 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-07-23 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-07-22 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-07-22 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-07-22 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-07-22 | Herabstufung | Wedbush | Outperform → Neutral |
| 2025-06-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-28 | Eingeleitet | ROTH MKM | Buy |
| 2023-04-17 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2020-11-17 | Eingeleitet | BTIG Research | Buy |
| 2020-11-02 | Eingeleitet | Jefferies | Buy |
| 2020-10-15 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-07-01 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-05 | Eingeleitet | Barclays | Overweight |
| 2019-09-04 | Eingeleitet | ROTH Capital | Buy |
| 2019-07-23 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-07-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-07-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-04-25 | Eingeleitet | Wedbush | Outperform |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-08-14 | Eingeleitet | JP Morgan | Overweight |
| 2018-08-14 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Replimune Group Inc Aktie (REPL) Neueste Nachrichten
REPL Stock On Track To Hit All-Time Lows – Here’s Why This Analyst Slashed Price Target By 85% - Stocktwits
REPL nosedives as FDA chief stands firm against melanoma treatment: ‘I don’t work for Replimune’ - MSN
REPL Stock On Track For Worst Drop In Nearly 7 Months Ahead Of FDA Decision On Skin Cancer Drug - Stocktwits
Replimune Group Stock Short Interest Rises to 56.4% - Quiver Quantitative
REPL stock soars on plans of BLA resubmission for melanoma combo drug - MSN
REPL Vs IOVA: FDA Decision Day Could Test Biotech Bulls’ Conviction On These Melanoma Plays - Stocktwits
Replimune: Modeling The Coin Flip Of FDA Approval - Seeking Alpha
Replimune CCO Sarchi sells $110,880 in stock By Investing.com - Investing.com South Africa
Insider Sell: Christopher Sarchi Sells 12,000 Shares of Replimune Group Inc (REPL) - GuruFocus
Replimune CCO Sarchi sells $110,880 in stock - Investing.com
Replimune (REPL) CCO sells 12,000 shares under 10b5-1 plan - Stock Titan
Replimune surges on plans to resubmit lead drug for FDA review - MSN
REPL Stock Shot Up 80% Today – What’s The Deal With FDA? - Stocktwits
REPL Maintains Rating by Wedbush -- Price Target Raised to $6.00 - GuruFocus
REPL Stock Soars on Plans of BLA Resubmission for Melanoma Combo Drug - Yahoo Finance
Replimune Group Price Target Raised to $6.00/Share From $2.00 by Wedbush - Moomoo
Replimune Group Is Maintained at Neutral by Wedbush - Moomoo
Why Is Replimune Stock Gaining Monday? - Benzinga
Replimune Group (REPL) Is Up 77.0% After FDA Prioritizes RP1 Melanoma BLA Resubmission PathHas The Bull Case Changed? - simplywall.st
Why is REPL stock gaining in pre-market today? - MSN
Why Is REPL Stock Gaining In Pre-Market Today? - Yahoo Finance
Replimune plans RP1 BLA resubmission - The Pharma Letter
Palomar Holdings, Replimune Group, Snowflake - TradingView
US FDA Consistency Questions Remain As Replimune Eyes Third Shot At RP1 Approval - Citeline News & Insights
JPMorgan upgrades Replimune stock rating on FDA resubmission path - Investing.com
JPMorgan upgrades Replimune stock rating on FDA resubmission path By Investing.com - Investing.com Australia
REPL Stock Quote Price and Forecast - CNN
Top Biotech Gainers: REPL On Track, SNSE Awaits Phase 2 Data, Keep An Eye On CCCC, IMRX Soars - RTTNews
REPL stock shot up 80% today – what’s the deal with FDA? - MSN
$Replimune (REPL.US)$ - Moomoo
Replimune (REPL) Reports Promising Survival Data from IGNYTE Tri - GuruFocus
Replimune (REPL) Reports Positive Data from RP2 Trials for Advan - GuruFocus
Replimune (REPL) Reports Positive Data from RP2 Trials for Advanced Tumors - GuruFocus
Replimune (REPL) Reports Promising Survival Data from IGNYTE Trial - GuruFocus
REPL Technical Analysis & Stock Price Forecast - Intellectia AI
Replimune Group Presents Final First-in-Human Data for RP2 Oncolytic Immunotherapy at ASCO 2026 - Quiver Quantitative
Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting - The Manila Times
Replimune (REPL) Gains FDA Support for RP1 Resubmission - GuruFocus
Replimune Group Inc. has released the latest data on its candidate therapy Rp1 in combination with nivolumab, showing remarkable long-term survival benefits in patients with advanced melanoma who have developed resistance to PD-1 therapies, with a me - Bitget
Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting - The Daily Tribune News
Replimune Group Says Rp1 Plus Nivolumab Achieves Median Overall Survival Of 32.9 Months In Anti-Pd-1-Failed Melanoma - TradingView
Nearly half of anti-PD-1-failed melanoma alive 3 years with Replimune combo - Stock Titan
Replimune gets third chance at US approval for skin cancer drug | Business Information & News | FE - Westlaw Today
How Replimune's Drug Got Third Chance After White House Intervention -- WSJ - Moomoo
Exclusive | How Replimune’s Drug Got Third Chance After White House Intervention - WSJ
Replimune takes third swing at cancer drug approval following ‘productive’ FDA talks - BioPharma Dive
Finanzdaten der Replimune Group Inc-Aktie (REPL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Replimune Group Inc-Aktie (REPL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Xynos Konstantinos | Chief Medical Officer |
May 18 '26 |
Sale |
5.08 |
14,023 |
71,237 |
235,662 |
| Schwendenman Andrew | Chief Accounting Officer |
May 18 '26 |
Sale |
5.08 |
7,894 |
40,102 |
107,057 |
| Sarchi Christopher | Chief Commercial Officer |
May 18 '26 |
Sale |
5.08 |
8,626 |
43,820 |
192,962 |
| Astley-Sparke Philip | Director |
May 18 '26 |
Sale |
5.08 |
17,657 |
89,698 |
1,412,414 |
| Patel Sushil | Chief Executive Officer |
May 18 '26 |
Sale |
5.08 |
37,324 |
189,606 |
747,492 |
| Hill Emily Luisa | Chief Financial Officer |
May 18 '26 |
Sale |
5.08 |
7,812 |
39,685 |
236,556 |
| Sarchi Christopher | Chief Commercial Officer |
Apr 02 '26 |
Sale |
8.01 |
6,500 |
52,065 |
151,588 |
1.61%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):